Search results for "Clinical Practice"

showing 10 items of 401 documents

Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world

2019

Background: Flow cytometry (FC) is a valuable tool for the diagnosis of myelodysplastic syndromes (MDS). We present results of a survey carried out to evaluate FC current practice for MDS diagnosis in Latin America (LA), focusing on markers used and characteristics of the clinical diagnostic report. Compliance to IMDSflow recommendations was also evaluated. These practices were then compared with those used in other countries. Methods: An online survey was sent through the Grupo Latino-Americano de Mielodisplasia to LA cytometrists and other international scientific societies. Results: 91 responses from 15 LA countries were received. The median of the number of markers used was 20 +/- 4.5, …

CanadaCancer Researchmedicine.medical_specialtyAsiaLatin AmericansOceaniaImmunophenotyping03 medical and health sciencesEuropean LeukemiaNet0302 clinical medicineSurveys and QuestionnairesDiagnosismedicineHumansFlow cytometryPractice Patterns Physicians'SurveyGeographybusiness.industryMyelodysplastic syndromesHematologyFlow Cytometrymedicine.diseaseUnited StatesEuropeClinical PracticeLatin AmericaOncologyCurrent practiceMyelodysplastic Syndromes030220 oncology & carcinogenesisFamily medicineAfricabusinessMyelodysplastic syndromeBackground flowBiomarkers030215 immunologyLeukemia Research
researchProduct

Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment†

2020

### Highlights There is no clear definition of orphan symptoms. There is a group of symptoms that are seldom evaluated in most symptom assessment tools which can be considered as orphan symptoms.1 These are generally prevalent symptoms that are unaddressed in clinical practice, yet often not reported by the patients or by healthcare professionals.2 Orphan symptoms may be defined as symptoms not regularly assessed in clinical practice, and consequently little studied and not properly treated. No epidemiological or clinical studies generally exist to gauge the prevalence of the symptoms chosen; nevertheless, these symptoms are distressing for patients and their families. Orphan symptoms remai…

Cancer ResearchPediatricsmedicine.medical_specialtydiagnosisoncological therapiesMEDLINElcsh:RC254-282Quality of lifeEpidemiologymedicine1506Restless legs syndromeOriginal Researchtreatmentbusiness.industryEvidence-based medicineorphan symptomsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRectal tenesmusclinical practice guidelines; diagnosis; oncological therapies; orphan symptoms; treatmentOncologymedicine.symptombusinessMyoclonusclinical practice guidelinesMuscle crampESMO Open
researchProduct

Refining sorafenib therapy: lessons from clinical practice

2015

ABSTRACT  Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symp…

Cancer ResearchSettore SECS-P/06 - Economia ApplicataAntineoplastic AgentAge FactorChild–Pugh Bpostprogression treatmentresponse assessmentdose modificationClinical Trials as TopicLiver Neoplasmsadverse event managementAge FactorsChild-Pugh Bpostprogression treatmenthepatocellular carcinomaGeneral MedicinePrognosisadverse event management; child–Pugh B; dose modification; elderly hepatocellular carcinoma; mRECIST; postprogression treatment; eal-world data; response assessment; sorafenibelderly hepatocellular carcinomaCombined Modality Therapychild–Pugh BClinical PracticeTreatment OutcomeOncologyLiver Neoplasmeal-world dataHepatocellular carcinomaadverse event managementRetreatmentDisease Progressiondose modificationHumanmedicine.drugPhenylurea CompoundNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularDisease ResponsePrognosielderly hepatocellular carcinomaProtein Kinase InhibitorAntineoplastic AgentsmRECISTelderlymRECISTAdverse event management Child–Pugh B dose modification elderly hepatocellular carcinoma mRECIST postprogression treatment real-world data response assessment sorafenibmedicineChild–Pugh BHumansCombined Modality TherapyIntensive care medicineAdverse effectProtein Kinase InhibitorsDose Modificationreal-world databusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationSurgeryreal-world dataresponse assessmentsorafenibbusinessFuture Oncology
researchProduct

Median progression free survival (PFS) for patients treated with everolimus (EVE) plus exemestane (EXE) for HR plus mBC in routine clinical practice …

2017

e12547 Background: BRAWO is a non-interventional study, which enrolled more than 2400 patients (pts) with advanced/metastatic, hormone-receptor-positive and HER2-negative breast cancer treated with EVE and EXE. Main objectives are a) the impact of physical activity on efficacy and quality of life, b) prophylaxis and management of stomatitis in clinical routine, and c) the sequence of therapy when EVE is used in daily clinical practice. We report updated data of the 3rd interim analysis, including PFS. Methods: This updated analysis (data cut-off 18 Oct 2016) covers data of the first 1345 documented pts with at least one follow up under therapy. Here we describe the baseline characteristics…

Cancer Researchmedicine.medical_specialtyEverolimusbusiness.industryMedizinmacromolecular substancesmedicine.diseaseInterim analysisSurgerystomatognathic diseaseschemistry.chemical_compoundBreast cancerOncologyQuality of lifeExemestanechemistryInternal medicineotorhinolaryngologic diseasesmedicineRoutine clinical practiceProgression-free survivalbusinessStomatitismedicine.drug
researchProduct

Underuse of recommended secondary preventive therapies in current routine clinical practice

2013

Cardiovascular eventSecondary preventionmedicine.medical_specialtyEvidence-based practicebusiness.industryMedicineMedical historyRoutine clinical practiceCardiology and Cardiovascular MedicinebusinessIntensive care medicineFibrinolytic agentEuropean Heart Journal
researchProduct

Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV)

2020

El diagnóstico y tratamiento del melanoma en atención especializada es un campo en el que se han producido numerosos cambios. El objetivo de esta guía es ofrecer a los dermatólogos españoles una referencia para resolver las dudas clínicas más frecuentes basándose en la evidencia actual. Para la realización de esta guía se escogió a miembros del Grupo Español de Dermato-Oncología y Cirugía con experiencia en el tratamiento de estos tumores y con interés en participar en la elaboración de la guía. Se hizo una adaptación de las guías de práctica clínica existentes mediante el método ADAPTE: inicialmente se resumió el proceso de atención y se elaboraron las preguntas clínicas relevantes. Se sel…

Care processmedicine.medical_specialtyPractice guidelineHistologyVenereologySkin NeoplasmsBiopsyTerapéuticaAntineoplastic AgentsDermatologyTherapeutics030204 cardiovascular system & hematologyPathology and Forensic MedicineHutchinson's Melanotic Freckle03 medical and health sciences0302 clinical medicineDiagnòsticDiagnosismedicineRelevance (law)HumansAgree ii030212 general & internal medicineNeoplasm MetastasisMelanomaNeoplasm StagingEvidence-Based Medicinebusiness.industrySentinel Lymph Node BiopsyDiagnósticoDisease ManagementGuidelineDiagnosis Diagnóstico Guía de práctica clínica Melanoma Practice guideline Terapéutica TherapeuticsTerapèuticaPatient preferenceDermatologyCombined Modality TherapyClinical PracticeGuía de práctica clínicaMolecular Diagnostic Techniquesbusiness
researchProduct

Cirugía de liberación del túnel carpiano: variabilidad e impacto de la cirugía ambulatoria en la Comunidad Valenciana

2013

Objective: This study aimed to analyze variability in rates of carpal tunnel release surgery among the healthcare areas of the autonomous region of Valencia, and to evaluate the contribution of ambulatory surgery and referrals to private hospitals to the variability found. Methods: We carried out a cross-sectional, population-based study, describing the rates of carpal tunnel release surgery, standardized by age and sex, among areas in the region of Valencia in 2006. The observed variation was then analyzed using small-area analysis methods. Data from hospital admissions, referrals to private hospitals, population statistics and hospital resources were used to construct standardized rates, …

Carpal tunnel syndrome/surgerySíndrome del túnel carpiano/cirugíaClinical practice variationColaboración público-privadaPublic-private partnershipsVariabilidad en la práctica médicaAnálisis de áreas pequeñasSmall-area variation analysis
researchProduct

Does Childhood Psychological Abuse Contribute to Intimate Partner Violence Victimization? An Investigation Using the Childhood Experience of Care and…

2018

International audience; Although psychological abuse is recognized as a particularly insidious form of child abuse, research on the impact of this type of abuse related to intimate partner violence (IPV) is scant. This study examined the contribution of childhood psychological abuse to IPV in female victims and non-victims. Furthermore, it investigated the role of cumulative abuse in predicting IPV. The study included 38 women victims of IPV and 40 non-IPV women. All participants were investigated using the Childhood Experience of Care and Abuse Interview (CECA); the Revised Conflict Tactics Scale (CTS2) and the IPV History Interview were used to assess IPV in the last year and lifetime, re…

Child abuseCECA intervieweducation[SHS.PSY]Humanities and Social Sciences/PsychologyIntimate Partner Violencebehavioral disciplines and activities[SHS]Humanities and Social SciencesChildhood maltreatment5. Gender equalitySettore M-PSI/08 - Psicologia Clinicamental disordersSettore M-PSI/07 - Psicologia DinamicaHumans0501 psychology and cognitive scienceschildhood maltreatment family violence intimate partner violence psychological abuse CECA interview.Child AbusePsychological abuseChildApplied PsychologyCrime VictimsConflict tactics scale050901 criminology05 social sciencesBullyingsocial sciences16. Peace & justiceIntervention planningFamily violenceEmotional Abuse3. Good healthClinical PracticePsychological abuseClinical PsychologyDomestic violencepopulation characteristicsFemale0509 other social sciencesPsychology050104 developmental & child psychologyClinical psychology
researchProduct

Posicionamiento para el manejo de la hipertensión arterial en atención primaria a partir del análisis crítico de las guías americana (2017) y europea…

2019

The Scientific Societies of Primary Care, being the area in which there is a considerable prevalence of Arterial Hypertension (AHT), need to periodically evaluate the international guidelines for its management. This is particularly relevant when disparate guidelines make it difficult to make decisions in daily clinical practice. The present document has as its aim to analyse the changes and new developments proposed in the guidelines of the American College of Cardiology and the American Heart Association (ACC/AHA 2017), as well as in the guidelines of the European Society of Cardiology and European Society of Hypertension (ESC/ESH 2018). An analysis will be made of any differences, limita…

Clinical Practice03 medical and health sciences0302 clinical medicineNursingbusiness.industryPublic Health Environmental and Occupational HealthMedicine030212 general & internal medicinePrimary care030204 cardiovascular system & hematologyFamily PracticebusinessScientific societyMedicina de Familia. SEMERGEN
researchProduct

Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?

2018

The burden of cardiometabolic diseases continues to rise worldwide (1). Obesity, insulin resistance, atherogenic dyslipidemia, hypertension and intra-abdominal adiposity are strongly interrelated and are crucial determinants of heart failure (HF) (2).

Clinical PracticeAtherogenic dyslipidemiaInsulin resistancebusiness.industryMetabolic effectsHeart failuremedicineCardiology and Cardiovascular Medicinemedicine.diseaseBioinformaticsbusinessObesitySacubitril ValsartanCardiovascular Diagnosis and Therapy
researchProduct